Levy, Cynthia

Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non‐Hispanics

Levy, C., Naik, J., Giordano, C., Mandalia, A., O'Brien, C., Bhamidimarri, K. R., Schiff, E. R., & Martin, P. (2014) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 77

Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: Results of a pilot study

Levy, C., Harnois, D. M., Angulo, P., Jorgensen, R., & Lindor, K. D. (2005) · Liver International

Bone health and osteoporosis researchLiver Diseases and Immunity

Cited by 62

Inter- and intra-individual variation, and limited prognostic utility, of serum alkaline phosphatase in a trial of patients with primary sclerosing cholangitis

Trivedi, P. J., Muir, A. J., Levy, C., Bowlus, C. L., Manns, M. P., Lu, X., Crans, G., Chung, C., Subramanian, G. M., Myers, R. P., et al. (2021) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 55

Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis

Hedin, C. R. H., Sado, G., Ndegwa, N., Lytvyak, E., Mason, A., Montano-Loza, A., Gerussi, A., Saffioti, F., Thorburn, D., Nilsson, E., et al. (2020) · Clinical Gastroenterology and Hepatology

Inflammatory Bowel DiseaseLiver Diseases and Immunity

Cited by 52

Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis

John, B. V., Schwartz, K., Levy, C., Dahman, B., Deng, Y., Martin, P., Taddei, T. H., & Kaplan, D. E. (2021) · Hepatology Communications

Liver Diseases and ImmunityLiver Disease and Transplantation

Cited by 51

Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO

Younossi, Z. M., Afendy, A., Stepanova, M., Racila, A., Nader, F., Gomel, R., Safer, R., Lenderking, W. R., Skalicky, A., Kleinman, L., et al. (2018) · Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 48

Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps

van Erp, L. W., Cunningham, M., Narasimman, M., Ale Ali, H., Jhaveri, K., Drenth, J. P. H., Janssen, H. L. A., Levy, C., Hirschfield, G. M., Hansen, B. E., et al. (2020) · Liver International

Cholangiocarcinoma and Gallbladder Cancer StudiesLiver Diseases and Immunity

Cited by 46

Timing, management, and outcomes of liver transplantation in primary sclerosing cholangitis

Levy, C., & Martin, E. (2017) · Seminars in Liver Disease

Liver Diseases and ImmunityOrgan Transplantation Techniques and Outcomes

Cited by 46

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 39

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

Murillo Perez, C. F., Ioannou, S., Hassanally, I., Trivedi, P. J., Corpechot, C., van der Meer, A. J., Lammers, W. J., Battezzati, P. M., Lindor, K. D., Nevens, F., et al. (2023) · Liver International

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 39

Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Jones, D. E. J., Beuers, U., Bonder, A., Carbone, M., Culver, E., Dyson, J., Gish, R. G., Hansen, B. E., Hirschfield, G., Jones, R., et al. (2024) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 38

Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial

Jones, D., Carbone, M., Invernizzi, P., Little, N., Nevens, F., Swain, M. G., Wiesel, P., & Levy, C. (2023) · Hepatology Communications

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 37

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Hirschfield, G. M., Bowlus, C. L., Jones, D. E. J., Kremer, A. E., Mayo, M. J., Tanaka, A., Andreone, P., Jia, J., Jin, Q., Macías-Rodríguez, R. U., et al. (2026) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 34

A Fibrosis-Independent hepatic transcriptomic signature identifies drivers of disease progression in primary sclerosing cholangitis

Gindin, Y., Chung, C., Jiang, Z., Zhou, J. Z., Xu, J., Billin, A. N., Myers, R. P., Goodman, Z., Landi, A., Houghton, M., et al. (2021) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 23

Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results

Levy, C., Trivedi, P. J., Kowdley, K. V., Gordon, S. C., Bowlus, C. L., Londoño, M. C., Hirschfield, G. M., Gulamhusein, A., Lawitz, E. J., Vierling, J. M., et al. (2026) · American Journal of Gastroenterology

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 20